These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 15917531)

  • 1. Biological cost of single and multiple norfloxacin resistance mutations in Escherichia coli implicated in urinary tract infections.
    Komp Lindgren P; Marcusson LL; Sandvang D; Frimodt-Møller N; Hughes D
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2343-51. PubMed ID: 15917531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections.
    Komp Lindgren P; Karlsson A; Hughes D
    Antimicrob Agents Chemother; 2003 Oct; 47(10):3222-32. PubMed ID: 14506034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High frequency of aac(6')-Ib-cr gene associated with double mutations in gyrA and parC in Escherichia coli isolates from patients with urinary tract infections.
    Volcão LM; Lacava JP; Gewehr MF; Leal VL; Ramis IB; Ramos DF; Gonçalves CV; Possuelo LG; Minarini LAR; da Silva PEA; von Groll A
    J Glob Antimicrob Resist; 2018 Jun; 13():180-183. PubMed ID: 29307860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does mutation in gyrA and/or parC or efflux pump expression play the main role in fluoroquinolone resistance in Escherichia coli urinary tract infections?: A statistical analysis study.
    Shigemura K; Tanaka K; Yamamichi F; Shirakawa T; Miyake H; Fujisawa M
    Int J Antimicrob Agents; 2012 Dec; 40(6):516-20. PubMed ID: 23068598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a rapid assay for detecting gyrA mutations in Escherichia coli and determination of incidence of gyrA mutations in clinical strains isolated from patients with complicated urinary tract infections.
    Ozeki S; Deguchi T; Yasuda M; Nakano M; Kawamura T; Nishino Y; Kawada Y
    J Clin Microbiol; 1997 Sep; 35(9):2315-9. PubMed ID: 9276409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency of DNA gyrase and topoisomerase IV mutations and plasmid-mediated quinolone resistance genes among Escherichia coli and Klebsiella pneumoniae isolated from urinary tract infections in Azerbaijan, Iran.
    Azargun R; Soroush Barhaghi MH; Samadi Kafil H; Ahangar Oskouee M; Sadeghi V; Memar MY; Ghotaslou R
    J Glob Antimicrob Resist; 2019 Jun; 17():39-43. PubMed ID: 30445211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.
    Yasuda M; Fukuda H; Yokoi S; Ishihara S; Kawada Y; Deguchi T
    J Urol; 2000 Sep; 164(3 Pt 1):847-51. PubMed ID: 10953166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluoroquinolone resistance and gyrA and parC mutations of Escherichia coli isolated from chicken.
    Lee YJ; Cho JK; Kim KS; Tak RB; Kim AR; Kim JW; Im SK; Kim BH
    J Microbiol; 2005 Oct; 43(5):391-7. PubMed ID: 16273029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergence of a new mutation and its accumulation in the topoisomerase IV gene confers high levels of resistance to fluoroquinolones in Escherichia coli isolates.
    Moon DC; Seol SY; Gurung M; Jin JS; Choi CH; Kim J; Lee YC; Cho DT; Lee JC
    Int J Antimicrob Agents; 2010 Jan; 35(1):76-9. PubMed ID: 19781915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High prevalence of fluoroquinolone-resistant Escherichia coli strains isolated from urine clinical samples.
    Dehbanipour R; Khanahmad H; Sedighi M; Bialvaei AZ; Faghri J
    J Prev Med Hyg; 2019 Mar; 60(1):E25-E30. PubMed ID: 31041407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro selection of resistance in Escherichia coli and Klebsiella spp. at in vivo fluoroquinolone concentrations.
    Drago L; Nicola L; Mattina R; De Vecchi E
    BMC Microbiol; 2010 Apr; 10():119. PubMed ID: 20409341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 'Supermutators' found amongst highly levofloxacin-resistant E. coli isolates: a rapid protocol for the detection of mutation sites.
    Zayed AA; Essam TM; Hashem AG; El-Tayeb OM
    Emerg Microbes Infect; 2015 Jan; 4(1):e4. PubMed ID: 26038761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms involved in the development of resistance to fluoroquinolones in Escherichia coli isolates.
    Tavío MM; Vila J; Ruiz J; Ruiz J; Martín-Sánchez AM; Jiménez de Anta MT
    J Antimicrob Chemother; 1999 Dec; 44(6):735-42. PubMed ID: 10590273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interplay in the selection of fluoroquinolone resistance and bacterial fitness.
    Marcusson LL; Frimodt-Møller N; Hughes D
    PLoS Pathog; 2009 Aug; 5(8):e1000541. PubMed ID: 19662169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro selection of resistance to pradofloxacin and ciprofloxacin in canine uropathogenic Escherichia coli isolates.
    Liu X; Lazzaroni C; Aly SA; Thungrat K; Boothe DM
    Vet Microbiol; 2014 Dec; 174(3-4):514-522. PubMed ID: 25465666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of gyrA and parC mutations and prevalence of plasmid-mediated quinolone resistance genes in Escherichia coli and Klebsiella pneumoniae isolated from patients with urinary tract infection in Iran.
    Mirzaii M; Jamshidi S; Zamanzadeh M; Marashifard M; Malek Hosseini SAA; Haeili M; Jahanbin F; Mansouri F; Darban-Sarokhalil D; Khoramrooz SS
    J Glob Antimicrob Resist; 2018 Jun; 13():197-200. PubMed ID: 29747008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of the fitness burden of quinolone resistance in Pseudomonas aeruginosa.
    Kugelberg E; Löfmark S; Wretlind B; Andersson DI
    J Antimicrob Chemother; 2005 Jan; 55(1):22-30. PubMed ID: 15574475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates.
    Morgan-Linnell SK; Becnel Boyd L; Steffen D; Zechiedrich L
    Antimicrob Agents Chemother; 2009 Jan; 53(1):235-41. PubMed ID: 18838592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of mutations in DNA gyrase and topoisomerase IV genes to ciprofloxacin resistance in Escherichia coli clinical isolates.
    Bansal S; Tandon V
    Int J Antimicrob Agents; 2011 Mar; 37(3):253-5. PubMed ID: 21236644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae.
    Pan XS; Fisher LM
    Antimicrob Agents Chemother; 1998 Nov; 42(11):2810-6. PubMed ID: 9797208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.